BGV
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. The Company has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class companies. BGV manages over EUR 440 million investing in areas where true scientific innovations, unmet medical need, and the potential to demonstrate a significant proof of concept all converge. BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realization for its investors. BGV is the early-stage focused platform partner of Forbion, a leading life sciences venture capital fund with deep roots in Europe.
Angelini Ventures
Angelini Ventures is a global venture capital firm and part of Angelini Industries, a leading Italian multisector industrial group. Launched in 2022 with an initial €300 million capital commitment, the firm invests in companies developing breakthrough solutions in biotechnology, medtech, and digital health. To date, Angelini Ventures has built a portfolio of 24 companies across Europe and North America dedicated to extending life expectancy and improving patient outcomes. In December 2025, the firm expanded its impact through a €150 million co-financing partnership with the European Investment Bank. Angelini Ventures is headquartered in Rome, with a strategic presence in Singapore and Boston, and employs a team of over 20 professionals located across key life sciences hubs in Europe, Asia, and North America.
Kurma Partners
Founded in Paris in 2009, Kurma Partners, an Eurazeo group company, has established itself as a benchmark player in financing innovation to build the healthcare industry of tomorrow. Kurma invests in companies from inception through to growth stages, covering the entire healthcare spectrum through its various dedicated franchises. These have expanded alongside successive funds in early-stage biotechnology (Biofunds I, II, and III), early-stage digital health and diagnostics (Kurma Diagnostics and Kurma Diagnostics 2), and most recently, growth capital (Kurma Growth Opportunities Fund). The Kurma team consists of 25 professionals, including 10 partners, operating across two offices in Paris and Munich. They are deeply integrated into the European ecosystem and have woven a robust network of international connections with prestigious research institutes, hospitals, entrepreneurs, industry players, and peer investors. With this final closing, Kurma Partners’ total Assets Under Management (AUM) across all franchises reached €1 billion. Kurma Partners is part of the Eurazeo group.
ROM Utrecht Region
ROM Utrecht Region is a regional investment fund that increases access to capital, network and strategic expertise for innovative companies in the region. ROM invests in the major transition sectors that are important for tomorrow’s economy: Life Sciences & Health, Sustainability and New Digital Society. The Startup Innovation Fund (SIF) is partly commissioned by the European Regional Development Fund (ERDF). SIF invests in companies developing highly innovative technologies who also have the ambition to become scalable businesses and to grow. To enable funding for these companies, SIF co-invests with (private) investors.
Epidarex Capital
Epidarex Capital is a transatlantic venture capital firm that builds exceptional life science companies in emerging hubs in the US and UK. Epidarex’s experienced team of early-stage investors partner with entrepreneurs and leading research institutions to transform world-class science into highly innovative products addressing major unmet needs in global healthcare.
Vesalius Biocapital Partners
Vesalius is a specialist life sciences venture capital investor, investing in companies in later stage companies in drug development, medical device diagnostic and e-health since 2007. Vesalius Biocapital IV, launched in June 2023, targets first and best-in-class European life science companies in drug development and digital health.
Its investment portfolio is well balanced between drug development and non-drug development investments and committed to providing capital to science-backed innovation and ambitious entrepreneurs. The team is based in Europe to explore investment opportunities and valuation potential for the portfolio.
p53 Invest
P53 Invest is a Norwegian healthcare investment company focused on supporting innovative life sciences and healthcare businesses with the potential to transform patients’ lives. With a long-term investment approach, p53 partners with companies founded on strong science and disruptive technologies, helping ambitious teams translate breakthrough discoveries into impactful products and sustainable growth.
Kerna Ventures
Kerna Ventures is an early-stage venture capital firm focused on backing breakthrough therapeutic platform technologies emerging from leading academic institutions. Investing from seed through Series A, Kerna supports pioneering companies in areas such as genome engineering, cell reprogramming, and computational biology, helping translate cutting-edge science into transformative healthcare innovations.
© RougeTx
